dc.contributor.author | Anisdahl, Karoline | |
dc.contributor.author | Lirhus, Sandre Svatun | |
dc.contributor.author | Medhus, Asle Wilhelm | |
dc.contributor.author | Moum, Bjørn Allan | |
dc.contributor.author | Melberg, Hans Olav | |
dc.contributor.author | Høivik, Marte Lie | |
dc.date.accessioned | 2024-08-26T08:00:05Z | |
dc.date.available | 2024-08-26T08:00:05Z | |
dc.date.issued | 2024-03-02 | |
dc.description.abstract | Background/Aims: To determine real-world medical and surgical treatment patterns in elderly-onset inflammatory bowel disease in a nationwide cohort, and to investigate associations between frailty and
treatment choices.<p>
<p>Methods: Norwegian health registries were used to identify adult-onset (born 1950–1989) and elderlyonset (born 1910–1949) patients with Crohn’s disease (CD) and ulcerative colitis (UC) diagnosed 2010–
2017 (n = 13,006). Patients were classified as no, low and intermediate/high frailty risk after the Hospital
Frailty Risk Score. Outcomes included use of medical and surgical treatment.
<p>Results: Within five years, elderly-onset patients received less biologics (13% [CD], 7% [UC]) and immunomodulators (24% [CD], 11% [UC]), and major surgery was more frequent (22% [CD], 9% [UC]) than
in adult-onset. Respective log rank tests were significant (p < 0.01). Compared to no frailty risk groups,
elderly-onset UC with intermediate/high frailty risk had lower probability of starting biologics (4% versus
9%), immunomodulators (7% versus 13%) and 5-aminosalisylic acids (66% versus 84%), and elderly-onset
CD with intermediate/high frailty risk had higher probability of starting prednisolone (67% versus 49%).
Respective log rank tests were significant (p < 0.05).
<p>Conclusions: Elderly-onset patients received less biologics and immunomodulators and a larger proportion underwent major surgery. Frailty risk in elderly-onset patients was associated with increased use of
prednisolone, and less use of 5-aminosalisylic acids, immunomodulators and biologics. | en_US |
dc.identifier.citation | Anisdahl, Lirhus, Medhus, Moum, Melberg, Høivik. Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study. Digestive and Liver Disease. 2024 | en_US |
dc.identifier.cristinID | FRIDAID 2260499 | |
dc.identifier.doi | 10.1016/j.dld.2024.02.002 | |
dc.identifier.issn | 1590-8658 | |
dc.identifier.issn | 1878-3562 | |
dc.identifier.uri | https://hdl.handle.net/10037/34417 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Digestive and Liver Disease | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2024 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) | en_US |
dc.title | Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |